Section Arrow
ABUS.NASDAQ
- Arbutus Biopharma Corp
Quotes are at least 15-min delayed:2026/05/04 07:14 EDT
Pre Market
Last
 4.32
0 (0.00%)
Bid
4.22
Ask
4.32
High 4.36 
Low 4.31 
Volume 277 
Regular Hours (Closed)
Last
 4.32
+0.12 (+2.86%)
Day High 
4.335 
Prev. Close
4.2 
1-M High
4.75 
Volume 
922.03K 
Bid
4.22
Ask
4.32
Day Low
4.165 
Open
4.2 
1-M Low
4.01 
Market Cap 
827.15M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.34 
20-SMA 4.38 
50-SMA 4.44 
52-W High 5.1 
52-W Low 2.94 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.17/-0.07
Enterprise Value
827.35M
Balance Sheet
Book Value Per Share
0.39
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
14.08M
Operating Revenue Per Share
0.07
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LABTLakewood-Amedex Biotherapeutics Inc3.43+0.77+28.95%-- 
Pre Market 2.95 -0.48 -13.99%
CUECue Biopharma Inc.30.42+15.68+106.38%-- 
Pre Market 28.52 -1.9 -6.25%
SMMTSummit Therapeutics16.115-5.345-24.91%-- 
Pre Market 16.29 +0.175 +1.09%
SGMOSangamo Therapeutics0.135+0.0158+13.26%-- 
Pre Market 0.1285 -0.0065 -4.81%
OSRHOSR Holdings Inc.0.6366-0.0663-9.43%-- 
Pre Market 0.586 -0.0506 -7.95%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.